Ann Childress, MD

A Randomized, Placebo-Controlled Study of the Efficacy and Safety of SHP465 Mixed Amphetamine Salts Extended-Release in Children and Adolescents With ADHD: Exploratory Analyses by Age

Objectives: To evaluate SHP465 mixed amphetamine salts (MAS) extended-release efficacy, safety, and tolerability by age group in children and adolescents with attention-deficit/hyperactiv...

Ann Childress , MD;

Ming Yu , MD, PhD;

Brian Yan , PhD;

Brigitte Robertson , MD;

03/01/2019

A Phase 3, safety and efficacy, adult laboratory classroom study in subjects with Attention-Deficit/Hyperactivity Disorder (ADHD) using CTx-1301 (dexmethylphenidate).

Cingulate has conducted a Phase 3 randomized, placebo controlled efficacy and safety study along with onset and duration in 21 adults with ADHD using CTx-1301 in a laboratory classroom se...

Ann Childress , MD;

10/26/2023

Viloxazine ER (Qelbree®) Administered with Psychostimulants in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Topline Results of a Phase IV Safety Trial

Results of a phase IV, open-label safety study evaluating viloxazine ER (Qelbree®) administered with psychostimulants in pediatric (6-17 years) ADHD; morning vs. evening administration of...

Ann Childress , MD;

10/26/2023

A Randomized, Double-Blind, Placebo-Controlled Study of Delayed-Release and Extended-Release Methylphenidate in Children With ADHD: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings

Purpose: Evening-dosed HLD200 is a delayed-release and extended-release methylphenidate (DR/ER-MPH) designed to provide treatment effect in the early morning, throughout the day, and into...

Andrew J. Cutler , MD;

Ann Childress , MD;

Andrea Marraffino , PhD;

Norberto DeSousa , MA;

Bev Incledon , PhD;

F. Randy Sallee , MD, PhD;

Sharon Wigal , PhD;

11/22/2019

Early-Onset Efficacy and Safety Pilot Study of Amphetamine Extended-Release Oral Suspension (AMPH EROS) in the Treatment of Children With Attention-Deficit/Hyperactivity Disorder

Objective: Determine if AMPH EROS has an onset of effect at 30 minutes post-dose in children with ADHD.

Antonio Pardo , MD;

Barry Herman , MD, MMM;